

28 March 2025

**ONDINE BIOMEDICAL INC.**  
("Ondine Biomedical", "Ondine", or the "Company")

**Board Changes**

Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial treatments, announces that Mike Farrar has resigned from his position as Non-Executive Director of the Company, effective immediately, following his appointment by the Health Minister for Northern Ireland, Mike Nesbitt, as the Interim Permanent Secretary of the Northern Ireland Executive Department of Health.

**Carolyn Cross, CEO of Ondine Biomedical, commented:**

*"We are very grateful for Mr. Farrar's contributions and his unwavering support of the Company over the past four years and wish him great success in his important new role. Mr. Farrar's expertise and knowledge of healthcare delivery systems have been invaluable during this crucial period of growth and development, and we extend our sincere appreciation for his efforts and commitment to the success of our organization."*

**Enquiries:**  
**Ondine Biomedical Inc.**  
Carolyn Cross, CEO

[www.ondinebio.com](http://www.ondinebio.com)  
Via Vane Percy & Roberts

**Strand Hanson Limited (Nominated & Financial Adviser)**

James Harris, Richard Johnson

+44 (0)20 7409 3494

**RBC Capital Markets (Broker)**

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000

**Vane Percy & Roberts (Media Contact)**

Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

**About Ondine Biomedical Inc.**

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection') to prevent and treat infections, including those caused by antibiotic-resistant bacteria. Ondine's patented light-activated antimicrobial technology offers a safe, rapid, and effective alternative to traditional antibiotics, tackling some of the most pressing healthcare challenges today.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAJPMJMTATBJA